Molecular Partners AG
Molecular Partners AG (0QXX.L) Financial Performance & Income Statement Overview
Review Molecular Partners AG (0QXX.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Molecular Partners AG (0QXX.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Molecular Partners AG 0QXX.L financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $681000.00 | $1.55M | $2.74M |
| Cost of Revenue | $0.00 | $0.00 | $13.09M | $14.10M |
| Gross Profit | $0.00 | $681000.00 | -$11.54M | -$11.37M |
| Gross Profit Ratio | $0.00 | $1.00 | -$7.44 | -$4.15 |
| R&D Expenses | $10.55M | $10.86M | $13.09M | $14.10M |
| SG&A Expenses | $3.83M | $4.41M | $3.84M | $3.89M |
| Operating Expenses | $14.79M | $15.27M | $16.92M | $17.99M |
| Total Costs & Expenses | $14.79M | $15.27M | $17.53M | $18.60M |
| Interest Income | $651000.00 | $718000.00 | $912000.00 | $1.10M |
| Interest Expense | $9000.00 | $9000.00 | $6000.00 | $7000.00 |
| Depreciation & Amortization | $570000.00 | $591000.00 | $603000.00 | $605000.00 |
| EBITDA | -$10.65M | -$15.80M | -$14.47M | -$10.71M |
| EBITDA Ratio | -$23.21 | -$9.33 | -$3.91 | |
| Operating Income | -$14.79M | -$14.59M | -$15.98M | -$15.86M |
| Operating Income Ratio | -$21.42 | -$10.30 | -$5.79 | |
| Other Income/Expenses (Net) | $3.56M | -$1.81M | $894000.00 | $4.53M |
| Income Before Tax | -$11.23M | -$16.40M | -$15.08M | -$11.32M |
| Income Before Tax Ratio | -$24.09 | -$9.72 | -$4.14 | |
| Income Tax Expense | $2000.00 | $0.00 | $0.00 | $561724.00 |
| Net Income | -$11.23M | -$16.40M | -$15.08M | -$11.32M |
| Net Income Ratio | -$24.09 | -$9.72 | -$4.14 | |
| EPS | -$0.33 | -$0.49 | -$0.45 | -$0.34 |
| Diluted EPS | -$0.33 | -$0.49 | -$0.45 | -$0.34 |
| Weighted Avg Shares Outstanding | $36.86M | $33.19M | $33.18M | $32.87M |
| Weighted Avg Shares Outstanding (Diluted) | $36.86M | $33.19M | $33.18M | $32.87M |
The company's financials show resilient growth, with revenue advancing from $2.74M in Q1 2024 to $0.00 in Q4 2024. Gross profit remained healthy with margins at N/A in Q4 2024 compared to -415% in Q1 2024. Operating income hit -$14.79M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$10.65M. Net income rose to -$11.23M, while earnings per share reached -$0.33. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan